用于癌症治疗的工程化T细胞。
Engineered T cells for cancer therapy.
作者信息
June Carl H, Maus Marcela V, Plesa Gabriela, Johnson Laura A, Zhao Yangbing, Levine Bruce L, Grupp Stephan A, Porter David L
机构信息
Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 8th Floor, Philadelphia, PA, 19104-5156, USA,
出版信息
Cancer Immunol Immunother. 2014 Sep;63(9):969-75. doi: 10.1007/s00262-014-1568-1. Epub 2014 Jun 19.
Abstract
It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this focused research review.
摘要
现在已经充分证实，免疫系统能够控制并消除癌细胞。在通常免疫功能受损的患者中，过继性T细胞转移有可能克服与基于疫苗的策略相关的重大局限性。合成生物学这一新兴学科在癌症领域的应用，即将基因工程和分子生物学元素结合起来以创造具有增强功能的新生物结构，是本重点研究综述的主题。
相似文献
1
Engineered T cells for cancer therapy.
Cancer Immunol Immunother. 2014 Sep;63(9):969-75. doi: 10.1007/s00262-014-1568-1. Epub 2014 Jun 19.
2
T cell engineering as therapy for cancer and HIV: our synthetic future.
Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140374. doi: 10.1098/rstb.2014.0374.
3
Redirected T cells in cancer therapy.
Expert Opin Biol Ther. 2015;15(12):1667-70. doi: 10.1517/14712598.2015.1096340. Epub 2015 Oct 29.
4
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
Annu Rev Immunol. 2017 Apr 26;35:229-253. doi: 10.1146/annurev-immunol-051116-052302.
5
Strategies to genetically engineer T cells for cancer immunotherapy.
Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2.
6
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.
Nat Biotechnol. 2016 Apr;34(4):430-4. doi: 10.1038/nbt.3461. Epub 2016 Feb 22.
7
Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
Immunotherapy. 2017 Dec;9(16):1339-1349. doi: 10.2217/imt-2017-0103.
8
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Int Immunol. 2016 Jul;28(7):349-53. doi: 10.1093/intimm/dxw022. Epub 2016 Apr 28.
9
CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Methods Mol Biol. 2020;2086:1-10. doi: 10.1007/978-1-0716-0146-4_1.
10
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
引用本文的文献
1
Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.
Med Oncol. 2025 Jun 15;42(7):261. doi: 10.1007/s12032-025-02808-z.
2
Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities.
Biotechnol Adv. 2025 Sep;82:108592. doi: 10.1016/j.biotechadv.2025.108592. Epub 2025 May 3.
3
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity.
Elife. 2024 Jun 17;12:RP91999. doi: 10.7554/eLife.91999.
4
Advancements in Cell-Based Therapies for HIV Cure.
Cells. 2023 Dec 28;13(1):64. doi: 10.3390/cells13010064.
5
The U.S. Food and Drug Administration, the mechanism of action, and other considerations for cell-based therapy candidates.
Exp Biol Med (Maywood). 2023 Jul;248(13):1173-1180. doi: 10.1177/15353702231194250. Epub 2023 Aug 26.
6
Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling.
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1577-1590. doi: 10.1002/psp4.13011. Epub 2023 Jul 28.
7
Smart Design of Nanostructures for Boosting Tumor Immunogenicity in Cancer Immunotherapy.
Pharmaceutics. 2023 May 7;15(5):1427. doi: 10.3390/pharmaceutics15051427.
8
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118413. doi: 10.1177/15330338221118413.
9
Systematic Review of Available CAR-T Cell Trials around the World.
Cancers (Basel). 2022 May 27;14(11):2667. doi: 10.3390/cancers14112667.
10
Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action.
Antib Ther. 2021 Oct 22;4(4):228-241. doi: 10.1093/abt/tbab024. eCollection 2021 Oct.
本文引用的文献
1
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
2
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
3
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
4
Toxicity management for patients receiving novel T-cell engaging therapies.
Curr Opin Pediatr. 2014 Feb;26(1):43-9. doi: 10.1097/MOP.0000000000000043.
5
Chimeric antigen receptor therapy for cancer.
Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20.
6
Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.
J Immunol. 2013 Sep 15;191(6):3232-9. doi: 10.4049/jimmunol.1301270. Epub 2013 Aug 12.
7
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.
8
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
Immunity. 2013 Jul 25;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002.
9
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.
10
Perspective: assembly line immunotherapy.
Nature. 2013 Jun 27;498(7455):S17. doi: 10.1038/498S17a.
Zotero 插件